source
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 2mo ago↗ source
- Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma ManagementAjai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.onclive · 2mo ago↗ source
- Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment DurationNew SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.onclive · 2mo ago